Indoco Remedies Limited
Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides bra… Read more
Indoco Remedies Limited (INDOCO) - Net Assets
Latest net assets as of September 2025: ₹9.74 Billion INR
Based on the latest financial reports, Indoco Remedies Limited (INDOCO) has net assets worth ₹9.74 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹25.08 Billion) and total liabilities (₹15.34 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹9.74 Billion |
| % of Total Assets | 38.85% |
| Annual Growth Rate | 12.37% |
| 5-Year Change | 32.43% |
| 10-Year Change | 74.29% |
| Growth Volatility | 20.05 |
Indoco Remedies Limited - Net Assets Trend (2004–2025)
This chart illustrates how Indoco Remedies Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Indoco Remedies Limited (2004–2025)
The table below shows the annual net assets of Indoco Remedies Limited from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹10.18 Billion | -8.30% |
| 2024-03-31 | ₹11.10 Billion | +8.00% |
| 2023-03-31 | ₹10.28 Billion | +13.66% |
| 2022-03-31 | ₹9.05 Billion | +17.64% |
| 2021-03-31 | ₹7.69 Billion | +13.16% |
| 2020-03-31 | ₹6.80 Billion | +2.87% |
| 2019-03-31 | ₹6.61 Billion | -2.13% |
| 2018-03-31 | ₹6.75 Billion | +3.60% |
| 2017-03-31 | ₹6.52 Billion | +11.51% |
| 2016-03-31 | ₹5.84 Billion | +12.63% |
| 2015-03-31 | ₹5.19 Billion | +13.43% |
| 2014-03-31 | ₹4.57 Billion | +10.47% |
| 2013-03-31 | ₹4.14 Billion | +7.61% |
| 2012-03-31 | ₹3.85 Billion | +9.87% |
| 2011-03-31 | ₹3.50 Billion | +12.78% |
| 2010-03-31 | ₹3.11 Billion | +11.52% |
| 2009-03-31 | ₹2.78 Billion | +9.52% |
| 2008-03-31 | ₹2.54 Billion | +9.11% |
| 2007-03-31 | ₹2.33 Billion | +17.46% |
| 2006-03-31 | ₹1.98 Billion | +13.16% |
| 2005-03-31 | ₹1.75 Billion | +99.20% |
| 2004-03-31 | ₹880.11 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Indoco Remedies Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 672165100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹6.72 Billion | 65.77% |
| Common Stock | ₹184.50 Million | 1.81% |
| Other Comprehensive Income | ₹2.65 Billion | 25.91% |
| Other Components | ₹665.57 Million | 6.51% |
| Total Equity | ₹10.22 Billion | 100.00% |
Indoco Remedies Limited Competitors by Market Cap
The table below lists competitors of Indoco Remedies Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Charlton Aria Acquisition Corporation Units
NASDAQ:CHARU
|
$84.04 Million |
|
Dimeco Inc
OTCQX:DIMC
|
$84.10 Million |
|
Helloworld Travel Ltd
AU:HLO
|
$84.14 Million |
|
TCPL Packaging Limited
NSE:TCPLPACK
|
$84.14 Million |
|
YUEXIU SERVICES GROUP LTD
F:5R9
|
$83.96 Million |
|
G Willi-Food International Ltd
NASDAQ:WILC
|
$83.95 Million |
|
SELECTQUOTE INC. DL -01
F:6SJA
|
$83.95 Million |
|
Third Harmonic Bio Inc.
NASDAQ:THRD
|
$83.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Indoco Remedies Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 11,099,001,000 to 10,220,000,000, a change of -879,001,000 (-7.9%).
- Net loss of 737,400,000 reduced equity.
- Dividend payments of 139,000,000 reduced retained earnings.
- Share repurchases of 15,900,000 reduced equity.
- New share issuances of 15,900,000 increased equity.
- Other comprehensive income increased equity by 28,835,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹-737.40 Million | -7.22% |
| Dividends Paid | ₹139.00 Million | -1.36% |
| Share Repurchases | ₹15.90 Million | -0.16% |
| Share Issuances | ₹15.90 Million | +0.16% |
| Other Comprehensive Income | ₹28.84 Million | +0.28% |
| Other Changes | ₹-31.44 Million | -0.31% |
| Total Change | ₹- | -7.92% |
Book Value vs Market Value Analysis
This analysis compares Indoco Remedies Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.68x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 15.03x to 1.68x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-03-31 | ₹13.30 | ₹200.01 | x |
| 2005-03-31 | ₹22.91 | ₹200.01 | x |
| 2006-03-31 | ₹22.37 | ₹200.01 | x |
| 2007-03-31 | ₹26.02 | ₹200.01 | x |
| 2008-03-31 | ₹27.59 | ₹200.01 | x |
| 2009-03-31 | ₹30.22 | ₹200.01 | x |
| 2010-03-31 | ₹33.70 | ₹200.01 | x |
| 2011-03-31 | ₹38.00 | ₹200.01 | x |
| 2012-03-31 | ₹41.75 | ₹200.01 | x |
| 2013-03-31 | ₹44.93 | ₹200.01 | x |
| 2014-03-31 | ₹49.61 | ₹200.01 | x |
| 2015-03-31 | ₹56.30 | ₹200.01 | x |
| 2016-03-31 | ₹63.41 | ₹200.01 | x |
| 2017-03-31 | ₹70.71 | ₹200.01 | x |
| 2018-03-31 | ₹73.25 | ₹200.01 | x |
| 2019-03-31 | ₹72.80 | ₹200.01 | x |
| 2020-03-31 | ₹73.75 | ₹200.01 | x |
| 2021-03-31 | ₹83.45 | ₹200.01 | x |
| 2022-03-31 | ₹98.17 | ₹200.01 | x |
| 2023-03-31 | ₹111.46 | ₹200.01 | x |
| 2024-03-31 | ₹118.46 | ₹200.01 | x |
| 2025-03-31 | ₹119.28 | ₹200.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Indoco Remedies Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.22%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.43%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 2.38x
- Recent ROE (-7.22%) is below the historical average (11.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 24.16% | 13.56% | 1.04x | 1.71x | ₹124.59 Million |
| 2005 | 14.28% | 12.90% | 0.68x | 1.63x | ₹75.11 Million |
| 2006 | 15.87% | 12.94% | 0.78x | 1.57x | ₹116.53 Million |
| 2007 | 18.04% | 12.90% | 0.94x | 1.49x | ₹187.37 Million |
| 2008 | 16.02% | 11.63% | 0.94x | 1.47x | ₹153.14 Million |
| 2009 | 10.81% | 11.46% | 0.63x | 1.49x | ₹22.52 Million |
| 2010 | 13.56% | 10.57% | 0.83x | 1.54x | ₹110.42 Million |
| 2011 | 14.60% | 10.57% | 0.86x | 1.61x | ₹160.98 Million |
| 2012 | 12.04% | 8.15% | 0.87x | 1.71x | ₹78.66 Million |
| 2013 | 10.30% | 6.77% | 0.91x | 1.66x | ₹12.54 Million |
| 2014 | 12.68% | 7.91% | 1.00x | 1.60x | ₹122.66 Million |
| 2015 | 15.96% | 9.66% | 1.01x | 1.63x | ₹309.32 Million |
| 2016 | 14.20% | 8.27% | 1.04x | 1.65x | ₹245.49 Million |
| 2017 | 11.83% | 7.03% | 0.92x | 1.84x | ₹119.06 Million |
| 2018 | 6.10% | 4.04% | 0.82x | 1.83x | ₹-263.37 Million |
| 2019 | -0.44% | -0.31% | 0.75x | 1.90x | ₹-689.66 Million |
| 2020 | 3.55% | 2.23% | 0.85x | 1.87x | ₹-438.40 Million |
| 2021 | 12.10% | 7.64% | 0.93x | 1.71x | ₹161.46 Million |
| 2022 | 17.11% | 10.29% | 1.01x | 1.64x | ₹643.36 Million |
| 2023 | 13.83% | 8.67% | 0.99x | 1.61x | ₹394.25 Million |
| 2024 | 8.87% | 5.51% | 0.83x | 1.93x | ₹-125.30 Million |
| 2025 | -7.22% | -4.43% | 0.69x | 2.38x | ₹-1.76 Billion |
Industry Comparison
This section compares Indoco Remedies Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $17,182,683,300
- Average return on equity (ROE) among peers: 11.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Indoco Remedies Limited (INDOCO) | ₹9.74 Billion | 24.16% | 1.57x | $84.00 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $366.97 Million | 3.51% | 2.41x | $11.49 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $2.27 Million | -2.03% | 0.10x | $351.56 Million |
| Abbott India Limited (ABBOTINDIA) | $11.96 Billion | 21.35% | 0.35x | $1.60 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $37.90 Billion | 24.28% | 0.32x | $1.51 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.79 Million |
| Albert David Limited (ALBERTDAVD) | $1.86 Billion | 5.29% | 0.56x | $16.25 Million |
| Alivus Life Sciences Limited (ALIVUS) | $21.38 Billion | 21.84% | 0.26x | $329.34 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $1.71 Billion | 11.38% | 0.30x | $5.51 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $964.67 Million | 9.99% | 0.49x | $81.74 Million |